Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology, Inc. (Tactile Medical) (Nasdaq: TCMD) is a medical technology company that develops and markets at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. This news page aggregates company announcements, financial updates and clinical data releases related to TCMD stock and its underlying business.
Investors and healthcare observers can find earnings releases and quarterly financial results, where Tactile Medical reports revenue from its lymphedema and airway clearance product lines, along with metrics such as gross margin, operating income, net income and Adjusted EBITDA as defined by the company. These updates often include commentary on business priorities, share repurchase activity and outlook ranges for full-year revenue and Adjusted EBITDA.
The news flow also features clinical and scientific developments, including randomized controlled trial data on Flexitouch Plus for head and neck cancer-related lymphedema. Company press releases describe symptom improvements, swelling reduction and quality-of-life outcomes associated with its advanced pneumatic compression devices, as well as presentations at major medical meetings such as the American Society of Clinical Oncology and the American Congress of Rehabilitation Medicine.
In addition, this page includes notices of upcoming conference calls, investor conference presentations and other corporate events. Readers following TCMD news can use this feed to monitor how Tactile Medical communicates its strategy in at-home therapies, its collaboration with clinicians and durable medical equipment partners, and its efforts to expand access to care for patients with chronic lymphatic and pulmonary disorders. Bookmark this page for a centralized view of Tactile Systems Technology’s latest press releases and public disclosures.
Tactile Systems Technology (TCMD) has announced its participation in several upcoming investor conferences. Management will engage in virtual 1x1 meetings at the Oppenheimer Fall MedTech Summit on November 12 and at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19. Additionally, a fireside chat will take place during the 32nd Annual Piper Sandler Healthcare Conference from December 1 to 3, accessible via the company’s investor relations website. This participation underscores TCMD's commitment to advancing at-home therapies for chronic conditions.
Tactile Systems Technology (TCMD) reported a 1% decrease in Q3 2020 revenue to $49.1 million compared to $49.6 million in Q3 2019, with COVID-19 impacting results. Operating income fell 44% to $1.8 million, while adjusted EBITDA was $6.0 million, down from $6.4 million year-over-year. The company experienced a net loss of $12.7 million for the nine months ending September 30, 2020. Updated revenue guidance suggests a full-year decline of 1% to 2% year-over-year, with expectations for modest growth in Q4.
Tactile Systems Technology, Inc. (TCMD) will release its third-quarter fiscal 2020 financial results after market close on November 2. A conference call will be held at 5:00 PM ET on the same day for a detailed discussion of the results, accessible via phone and live webcast. Tactile Medical specializes in at-home treatment devices for chronic diseases like lymphedema and chronic venous insufficiency, aiming to enhance patient quality of life while reducing overall healthcare costs.
Tactile Systems Technology (Nasdaq: TCMD) has announced its participation in the Canaccord Genuity 40th Annual Global Growth Conference on August 12th at 2:00 p.m. Eastern Time. The conference will be held virtually, and management will engage in a fireside chat. Interested parties can access a live audio webcast through the company’s investor relations website, with an archive available for later replay. Tactile Medical focuses on at-home therapies for chronic diseases, notably with their pneumatic compression devices for conditions like lymphedema.
Tactile Systems Technology, Inc. (Nasdaq: TCMD) reported a 22% decrease in second quarter revenue, totaling $35.1 million, down from $45.2 million in 2019, largely due to COVID-19 pandemic impacts. The operating loss surged to $8.0 million, contrasting with a $3.0 million profit in 2019. The company incurred a net loss of $13.9 million, or $(0.72) per diluted share. Despite challenges, management noted improvements in June compared to earlier months, and remains optimistic about recovery and growth in the $5 billion U.S. lymphedema market.
Tactile Medical (Nasdaq:TCMD) will release its second quarter fiscal 2020 financial results on August 3, after market close. The company's management will host a conference call at 5:00 p.m. ET to discuss the results, which can be accessed by dialing 877-407-3088 (international: 201-389-0927) with access code 13705943. A live webcast will also be available on Tactile Medical's investor relations website. The company specializes in developing devices for at-home treatment of chronic diseases, notably lymphedema and chronic venous insufficiency, aiming to improve patient care and reduce healthcare costs.
Tactile Systems Technology, Inc. (Nasdaq: TCMD) announced the appointment of Daniel L. Reuvers as President and CEO, effective June 8, 2020, succeeding Gerald R. Mattys, who is retiring after 15 years of service. Reuvers, with over 30 years in the medical device industry, is expected to lead the company’s next growth phase. His previous role at Integra LifeSciences involved significant business leadership. Mattys will provide consulting until June 2021 for a smooth transition. The company focuses on at-home treatments for chronic diseases like lymphedema.
Summary not available.